Publications by authors named "B E Goulden"
Article Synopsis
- A study examined the outcomes of 25 pregnant women treated with IL-6 receptor antibodies for COVID-19 during their pregnancies at two hospitals in London from March 2020 to September 2022.
- Most women were in critical condition; 16 were treated in the third trimester, and all required multiple medications.
- Results indicated no serious maternal health issues, with all pregnancies resulting in live births, although there were complications, including 16 preterm births and one neonatal death due to severe prematurity.
Acutely silencing specific neurons informs about their functional roles in circuits and behavior. Existing optogenetic silencers include ion pumps, channels, metabotropic receptors, and tools that damage the neurotransmitter release machinery. While the former hyperpolarize the cell, alter ionic gradients or cellular biochemistry, the latter allow only slow recovery, requiring de novo synthesis.
View Article and Find Full Text PDFObjectives: An increased risk of adverse maternal and foetal pregnancy complications (including pre-eclampsia, intrauterine growth restriction, and small for gestational age) is well described in women with autoimmune rheumatic disease (ARD) compared with the general population (GenPop). It is less clear, however, whether this risk of adverse pregnancy outcome (APO) also exists in women with 'preclinical ARD' (pre-ARD) before they are diagnosed with an ARD many years post-partum. Therefore, we have undertaken a systematic review of the available evidence on APO in patients who subsequently were diagnosed with a rheumatic disease to identify whether there is an increased risk in pre-ARD.
View Article and Find Full Text PDFObjectives: To investigate predictors of sustained complete remission (CR) for 3 and 5 years, minimum.
Methods: Retrospective observational study from January 1978 to December 2019, including systemic lupus erythmatosus (SLE) patients who attended the Lupus Clinic in a tertiary hospital, for at least 3 years. We used the BILAG score and serological profile to classify patients into CR, serologically active clinically quiescent (SACQ) and serological remission (SR).